Articles tagged with Prostate Cancer
Researchers at Johns Hopkins Medicine developed a proof-of-principle urine test detecting prostate cancer using RNA and metabolites in the urine. The test identified cancer-specific changes in urinary RNAs and metabolites that may lead to future development of a noninvasive diagnostic tool.
A new study suggests that lengthening the time between prostate cancer screenings can significantly reduce overdiagnosis and improve outcomes. The research found that discontinuing screening at age 60 would greatly reduce overdiagnoses by 79-82%, but save fewer lives compared to screening until age 69.
A new study identifies a strong cancer driver gene linked to alternative splicing changes in aggressive cancers. The researchers developed computational tools and biological model systems to analyze RNA sequences from nearly 900 prostate tissue samples, revealing over 13,000 alternative splicing events.
Researchers found a genetic variant associated with aggressive disease and shorter survival in men with metastatic prostate cancer. Genetic testing for the HSD3B1(1245C) variant may help identify patients most likely to benefit from additional treatment.
A new study published in The Journal of Urology found that most patients who underwent prostate cancer surgery experienced low levels of decision regret. Patients who played a more active role in treatment decision-making were less likely to experience regret about their choices, regardless of whether they opted for robot-assisted or o...
Research found that statins, alone or with metformin, increase survival in men with high-risk prostate cancer. Metformin plus statin was associated with a 36% reduction in risk of death compared to non-users, while statins alone showed a 54% reduction in PCA mortality among patients with high-risk prostate cancer.
Researchers analyzed DNA data from African American and Caucasian American men with prostate cancer, finding lower frequencies of pathogenic/likely alterations in 14 well-characterized DNA repair genes among African Americans. The study suggests a higher risk for germline BRCA mutations but lower risks for non-BRCA mutations
Researchers identified novel PMEPA1-e isoform and characterized its biological functions in prostate cancer. The study found that the methylation of PMEPA1 gene promoter accounts for silencing of PMEPA1 in prostate cancer cells.
A new approach inhibiting FABP5 may halt disease progression in metastatic prostate cancer. Researchers developed novel FABP5 inhibitors exhibiting significant cytotoxicity against highly drug-resistant cells.
A five-year follow-up study of over 2,000 U.S. men with localized prostate cancer found that radiation therapy was associated with significant declines in erectile function, while surgery improved function over time. Prostatectomy also resulted in worse urinary incontinence compared to other treatments.
In an equal-access health care system, African American men with prostate cancer did not have more advanced disease at diagnosis or die earlier than white men. Access to high-quality medical care may help address racial disparities in prostate cancer outcomes.
A Phase III clinical trial found that eating seven or more servings of vegetables and fruits daily did not provide extra protection against prostate cancer. Despite this, a healthy diet rich in fruits and vegetables may help patients tolerate cancer treatments.
A randomized clinical trial found that a telephone-based program encouraging increased vegetable consumption did not decrease the risk of prostate cancer progression over two years. The study suggested that the intervention may have been underpowered to identify a clinically important difference in cancer progression.
Researchers at Radboud University Medical Center developed an AI system that accurately diagnoses prostate cancer aggressiveness using deep learning. The system performed better than ten human pathologists and provided consistent results, reducing the need for subjective Gleason scoring.
Researchers developed an AI system that can detect and grade prostate cancer with accuracy comparable to world-leading uro-pathologists. The system has the potential to significantly reduce the workload of uro-pathologists and improve diagnostic quality.
In 2020, prostate cancer will claim the most diagnoses among male cancers, with a 21% share of new cases. Early detection is crucial, but screening's benefits are disputed by some, leading to fewer men taking proactive steps towards their health.
Researchers are assembling the largest dataset of veterans with either condition or both to compare conditions and outcomes. They hope to find correlations between mental health and prostate cancer aggressiveness and explore biological risks like inflammation.
A new study suggests that targeted screening for men at higher genetic risk of prostate cancer could prevent nearly one in six deaths from the disease. The research modeled the harms and benefits of introducing four-yearly PSA screening for all men aged 55 to 69 versus more targeted checks for those at higher risk.
A new study published in BJU International found that short-term exercise can reduce the adverse effects of hormone therapy on cardiovascular fitness and fatigue. Patients who underwent supervised aerobic and resistance training experienced improved cardiopulmonary fitness, reduced fatigue, and enhanced quality of life.
The Milton and Carroll Petrie Department of Urology at Mount Sinai has received a $1 million grant from The Arthur M. Blank Family Foundation to fund the Prostate Cancer Program. The program aims to advance immunotherapy and personalized genomic vaccine trials aimed at treating prostate cancer.
Researchers found luteolin suppresses both early stage prostate carcinogenesis and CRPC by inducing apoptosis. MicroRNA-8080 (miR-8080) recruited by luteolin down-regulates AR-V7, inhibiting tumorigenesis and enzalutamide resistance in CRPC.
A large study published in International Journal of Epidemiology found that being more active reduces the risk of prostate cancer. Men with a specific DNA variation associated with increased physical activity had a 51% reduced risk, suggesting overall physical activity may play a larger role than previously thought.
Researchers established B6CaP, a prostate-derived tumor line that frequently metastasizes to bones and grows in an immunocompetent host, overcoming limitations of previous models. This model is useful for studying mechanisms of bone metastasis and tumor immune response.
A team of researchers identified a cell surface receptor, CXCR2, essential for hormone-resistant prostate cancer cells. They showed that targeting this receptor can halt tumor growth using a drug originally intended for lung diseases.
A clinical trial found that olaparib slowed or stopped tumour growth in men with advanced prostate cancer and BRCA mutations, with a median overall survival of 17.7 months. The study suggests that PARP inhibitors could become the first gene-targeted drug to be approved for prostate cancer.
A University of Colorado Cancer Center study suggests two new approaches to treating bone metastases from prostate cancer: targeting different signaling pathways for lytic and blastic lesions. Both types of bone metastases show promise with anti-cancer immunotherapy, particularly those with high PD-L1 levels.
A new study presents a novel MRI-guided procedure that effectively treats prostate cancer with minimal side effects. The technique, called TULSA, uses therapeutic ultrasound to destroy diseased prostate tissue while sparing healthy nerve tissue.
A new home urine test has shown to accurately diagnose aggressive prostate cancer and predict treatment needs up to five years earlier than standard clinical methods. The 'PUR' test looks at gene expression in urine samples and provides vital information about tumor aggressiveness.
A novel theranostic reagent has been developed to detect and treat metastatic prostate cancer, achieving high imaging accuracy. The reagent targets STEAP1 antigen, identifying lesions in patients with a significant number of positive results.
A new radiation therapy regimen combining lutetium-177 and actinium-225 has been shown to stabilize tumour growth and improve survival rates for patients with late-stage prostate cancer. The study demonstrated significant reductions in side effects, including dry mouth, compared to previous radionuclide therapies.
Men receiving care at multidisciplinary prostate cancer clinics are more likely to be informed about treatment options and receive evidence-based care, according to a new study. African American men also tend to opt for definitive therapy, challenging national trends.
Researchers at Intermountain Medical Center found that omega-3 fatty acids do not increase the risk of prostate cancer, contrary to earlier studies. High levels of omega-3s also showed a lower risk of adverse cardiovascular events and death in patients with severe coronary artery disease.
Researchers discover BRN4 overexpression drives neuroendocrine prostate cancer cell conversion in patients with recurrent cancer. Exosome inhibitors under study as potential treatment.
The UCLA prostate cancer program has been awarded an $8.7 million SPORE grant to develop new approaches for improving diagnosis, prognosis, and treatment of prostate cancer. The grant will fund three translational research projects to find better ways to treat men with advanced stages of the disease.
A large study of over 200,000 men found that high levels of 'free' testosterone and insulin-like growth factor-I (IGF-I) are associated with an increased risk of prostate cancer. The research suggests that these hormones could be modified to reduce prostate cancer risk, taking us a step closer to strategies for prevention.
A multi-centre registry trial is testing the use of a new PSMA tracer to detect early recurrence of prostate cancer. The trial provides valuable insights and has already shown promising results for patients like Wayne Smith, who was able to have a shorter round of hormone therapy.
A biomedical engineer at Worcester Polytechnic Institute is creating a new medical robot that uses photoacoustic imaging to detect and analyze three different indicators of prostate cancer. The system aims to be more accurate than current tests like ultrasounds and biopsies, while eliminating the need for radioactive contrast dye.
A comprehensive review of studies found a positive association between high dairy consumption and increased prostate cancer risk. In contrast, plant-based diets were associated with decreased risks of prostate cancer.
A study of over 13,000 cancer-free men found statin use was associated with a lower risk of developing prostate cancer. The association was strongest for aggressive tumors and only observed at high doses or long durations.
The study used the 18F-labelled PSMA-1007 radiotracer to detect recurrent and metastatic prostate cancer, which was not identified by conventional diagnostic imaging. The hospital aims to spread nuclear medicine that uses drugs labeled with α-emitting radionuclides for higher therapeutic effects.
A long-term cohort study of over 36,000 Japanese men found that consuming mushrooms on a regular basis reduces the risk of prostate cancer. Participants who ate mushrooms three or more times per week had a 17% lower risk compared to those who ate less frequently.
A study has identified a novel biomarker, KLK4-KLKP1 fusion gene, detectable in urine samples of patients with prostate cancer. This non-invasive method may replace traditional PSA tests, reducing unnecessary biopsies and improving diagnosis accuracy.
A new treatment approach for metastatic prostate cancer has shown promising results, delaying disease progression by more than double and potentially extending lives. The treatment targets genetic alterations that enable cancer cells to repair themselves, leading to significant extensions in time before the disease grows and spreads.
A recent study has shown that targeting faulty DNA repair mechanisms can slow the progression of advanced prostate cancer and improve survival rates. The PROfound trial demonstrated a significant delay in cancer progression with olaparib, compared to new hormonal agents, in patients with metastatic, pre-treated prostate cancer.
A national register study from Lund University found that fathers who underwent assisted reproduction, such as IVF and ICSI, had a 30-60% higher risk of developing prostate cancer compared to those who conceived naturally. The study also showed that men treated for infertility had a higher risk of prostate cancer at a young age.
A new analysis finds that long-term hormone therapy increases mortality risk for men with low PSA levels after prostate surgery. The study suggests that patients with high PSAs should continue to receive hormone therapy in addition to radiation, but those with low PSAs may be better off without it.
A randomized clinical trial found that high-dose radiation therapy can generate an immune system response similar to vaccination, sparking a systemic immune reaction against cancer. Patients treated with stereotactic ablative radiotherapy lived significantly longer without disease progression.
Researchers have discovered that certain molecules in semen, known as miRNAs, may serve as non-invasive biomarkers for prostate cancer. The study found that these molecules can provide reliable information to help diagnose and predict the progression of the disease.
Men who became fathers through assisted reproduction techniques have a higher risk of prostate cancer and early onset prostate cancer compared to those who conceived naturally. Early screening and long-term monitoring are advised for these men.
Researchers from the University of Bath screened over 20,000 molecules to find compounds that inhibit α-methylacyl-CoA racemase (AMACR) protein, increasing its levels in prostate cancer cells. This approach identified novel small-molecule inhibitors with potential therapeutic applications.
Researchers at George Washington University found a potential therapeutic target for prostate cancers with PTEN mutation by identifying the connection between PTEN and ARID4B genes. Suppressing ARID4B expression in cancer cells with PTEN mutation significantly inhibits cell growth and increases cell death.
Scientists at University of Bath have developed a new family of drugs that inhibit the AMACR protein, increasing effectiveness by 20-fold. The research provides promising avenues for treating prostate and other cancers.
A study found that men with the BRCA2 gene fault are almost twice as likely to be diagnosed with prostate cancer and develop more serious tumours. Regular PSA testing could help detect these cancers earlier.
The team aims to understand how genetics contributes to driving aggressive pathology in prostate cancer by combining pathology, computational modeling, and genomics. They plan to identify therapeutic options by testing combinations of genes in mouse models of the disease.
Researchers created a biosensor for detecting prostate cancer recurrence with high sensitivity and low cost. The device, like a home pregnancy test, provides immediate results and can help improve patient outcomes.
A new blood test detects early cancer cells in the bloodstream, predicting aggressive prostate cancer with high accuracy. Combining this test with the current PSA test reduces unnecessary biopsies and overtreatment of benign conditions.
A large cohort study found that obesity is consistently associated with a greater burden of symptoms and experiences of distress among patients with breast or prostate cancer. Among patients with colon cancer, significant symptoms and distress were observed regardless of weight, suggesting alternative factors at play.
A new study found an inverse relationship between mushroom consumption and the development of prostate cancer among middle-aged and elderly Japanese men. Regular mushroom intake was associated with an 8-17% lower risk of prostate cancer.
A new dual imaging approach combines transrectal ultrasound (TRUS) and photoacoustic imaging to detect anatomical features and molecular information of the prostate. This technology has shown promise in detecting prostate cancers with high accuracy, including distinguishing malignant regions in patients with advanced disease.
Researchers tested AuroLase Therapy, a treatment using gold-silica nanoshells, in 16 men with low- to intermediate-grade prostate cancer. The treatment was successful in 87.5 percent of lesions treated at one year of follow-up, preserving quality of life.